Publications

British journal of clinical pharmacology

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

01-10-2008

BMC clinical pharmacology

Long-term platinum retention after treatment with cisplatin and oxaliplatin.

17-09-2008

Antimicrobial agents and chemotherapy

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

01-08-2008

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

10-07-2008

Anti-cancer drugs

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.

01-07-2008

Clinical pharmacology and therapeutics

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.

01-06-2008

Pharmacogenetics and genomics

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

01-06-2008

British journal of cancer

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

22-04-2008

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

22-11-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

01-11-2007

British journal of clinical pharmacology

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

01-11-2007

Cancer chemotherapy and pharmacology

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.

01-10-2007

International archives of occupational and environmental health

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.

01-08-2007

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

01-07-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.

15-05-2007

Pharmaceutical research

Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

01-03-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

Flat dosing of carboplatin is justified in adult patients with normal renal function.

01-11-2006

British journal of cancer

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

09-10-2006

Journal of pharmacokinetics and pharmacodynamics

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.

01-10-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

01-10-2006

Nederlands tijdschrift voor geneeskunde

[Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].

23-09-2006

British journal of cancer

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

18-09-2006

Basic & clinical pharmacology & toxicology

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

01-08-2006

British journal of clinical pharmacology

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

01-07-2006

Drug metabolism and disposition: the biological fate of chemicals

Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.

01-06-2006

British journal of cancer

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.

08-05-2006

Therapeutic drug monitoring

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

01-12-2005

Clinical pharmacokinetics

Clinical pharmacokinetics of cyclophosphamide.

20-10-2005

Cancer chemotherapy and pharmacology

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.

01-10-2005

Investigational new drugs

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

01-06-2005

Therapeutic drug monitoring

Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).

01-06-2005

Cancer chemotherapy and pharmacology

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.

01-05-2005

Cancer chemotherapy and pharmacology

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.

01-05-2005

Anti-cancer drugs

Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.

01-03-2005

British journal of clinical pharmacology

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

01-03-2005

Clinical pharmacokinetics

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

20-01-2005

Clinical cancer research : an official journal of the American Association for Cancer Research

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

01-04-2004

Journal of pharmacokinetics and pharmacodynamics

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

01-04-2004

Journal of mass spectrometry : JMS

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-03-2004

Bone marrow transplantation

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

01-11-2002

Annals of oncology : official journal of the European Society for Medical Oncology

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

01-03-2002

Therapeutic drug monitoring

Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.

01-12-2001

Clinical pharmacology and therapeutics

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.

01-08-2001

Cancer chemotherapy and pharmacology

Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.

01-07-2001

Journal of chromatography. B, Biomedical sciences and applications

Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.

15-06-2001

Journal of pharmacokinetics and pharmacodynamics

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

01-06-2001

British journal of clinical pharmacology

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

01-01-2001

Therapeutic drug monitoring

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.

01-10-2000

Cancer chemotherapy and pharmacology

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

06-09-2000

Journal of chromatography. B, Biomedical sciences and applications

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

18-08-2000

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.

Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

Flat dosing of carboplatin is justified in adult patients with normal renal function.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

[Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

Clinical pharmacokinetics of cyclophosphamide.

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.

Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.

Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.

Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

This site uses cookies